AVIR Atea Pharmaceuticals, Inc.

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

$23.16  -0.29 (-1.24%)
As of 06/23/2021 15:59:54 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/30/2020
Outstanding shares:  82,736,937
Average volume:  1,378,938
Market cap:   $1,998,097,029
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04683R106
ISIN:        US04683R1068
Sedol:      BLN9Z50
Valuation   (See tab for details)
PE ratio:   37.77
PB ratio:   3.31
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy